TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04464434

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upfront autologous HSCT
Description: HSCT comprises the following consecutive steps:~1. Mobilisation~   * Infusions of CYC 2g/m2 on 1 day.~  * Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~  * Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~2. Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10\^6 CD34+ cells per kilogram body weight.~3. Conditioning~   * CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~  * Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~   Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~   I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~4. Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10\^6/kg.
Study: NCT02223715

Intervention type: OTHER
Intervention: CDI Pts
Study: NCT03316144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.
Study: NCT02181283

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: W+W
Description: Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Web booster sessions: Web boosters will be completed at 1, 2 and 3 months post-BI. Content is tailored to the individual based on answers to baseline questions and responses during Web-based BI. Web-based Booster will: 1) briefly ascertain current AOS use, 2) changes in AOS since completing Web BI, 3) progress toward goals, and 4) plans and encouragement for next steps.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: W+P
Description: Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Peer booster sessions: The peer supporter will work with participants at 1, 2, and 3 months post-Web-based BI. Peer supports will address Service Members' own goals and will provide emotional and informational support.
Study: NCT00930553

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.
Study: NCT03734003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: liquid nitrogen
Description: As an active comparator, for patients with cutaneous warts, liquid nitrogen crytherapy is applied

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: controllable infrared bioeffect system
Description: As an experimental arm, for patients with cutaneous warts
Study: NCT03769558

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT03912779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C2Hear RLOs
Description: Freely available online RLOs

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Printed hearing aid booklet
Description: Departmental printed hearing aid booklet (standard care)
Study: NCT02636530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ground Reaction Forces
Description: 6 month exercise program that loads the body via gravitational forces.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Reaction Forces
Description: 6 month exercise program that loads the body via loading the joints.
Study: NCT03015324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine
Study: NCT00318799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
Description: per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH D01155E
Description: per cycle: Days 1-21: 0.03 mg EE + 0.15 mg LNG; Days 22-28: Placebo
Study: NCT01090193

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Whipple operation,Hepaticojejunostomy
Description: Whipple operation, Hepaticojejunostomy
Study: NCT01485328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMARGOL®
Description: per oral solution, 40 mL single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMARGOL®
Description: per oral solution, 40 mL single dose
Study: NCT01015781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Tinnitus Management
Description: The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment. The five levels of progressive intervention are: 1) Triage; 2) Audiologic Evaluation; 3) Group Education; 4) Interdisciplinary Evaluation; 5) Individualized Support

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wait List Control
Description: VA audiologists typically (a) perform an audiologic evaluation; (b) fit hearing aids if necessary; and (c) provide basic information about tinnitus in the form of one-time, one-on-one informational counseling and/or a tinnitus handout. We therefore will provide these procedures for subjects who are randomized to receive usual care. Usual care subjects also can be referred for other clinical services as deemed appropriate.
Study: NCT02397538

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Study: NCT01199809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5310074
Description: multiple ascending doses
Study: NCT03132701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Mg is administered during anesthesia until 5 minutes before surgery ends

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Same volume of saline is infused until 5 minutes before surgery ends
Study: NCT01969695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: ABT-199 continuous once daily dosing
Study: NCT02104466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
Study: NCT00832416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Once A Day
Description: One Tramadol Once A Day tablet at randomized dose daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Once A Day
Description: One Tramadol Once A Day tablet at randomized dose daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Once A Day
Description: One Tramadol Once A Day tablet at randomized dose daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One Placebo tablet daily.
Study: NCT02895100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-100
Description: Daily dosing of PTG-100 by subject for a 12 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-100
Description: Daily dosing of PTG-100 by subject for a 12 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-100
Description: Daily dosing of PTG-100 by subject for a 12 week treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dosing of Placebo capsules by subject for a 12 week treatment period.
Study: NCT03484247

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: Infraclavicular block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration, via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: axillary brachial plexus block
Description: Axillary nerve block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
Study: NCT03782701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution 0.025%
Description: One time dosing of brimonidine tartrate ophthalmic solution 0.025% (1 drop applied to ocular surface)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sterile balanced saline solution
Description: One time dosing of sterile balanced saline solution (1 drop applied to ocular surface)
Study: NCT03306992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Exercise Program
Description: The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting).~For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face, virtual, or phone meetings (\~30-40 minutes). An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention.
Study: NCT01994616

Intervention type: PROCEDURE
Intervention: Intralesional cryotherapy
Description: Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
Study: NCT01761448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guide Exercise (GEx-)- Training
Description: Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities ( VO2 peak) of patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Exercise Training with an easy to wear vest with electrodes to measure ECG, respiration, activity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control group training without Guided Exercise system at home
Study: NCT02023957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive computer-assisted screening (iCAS)
Study: NCT01442714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine is thought to induce antineoplastic activity via two mechanisms; inhibition of DNA methyltransferase at low doses, causing hypomethylation of DNA, and direct cytotoxicity in abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA at high doses, resulting in cell death

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide has been used to successfully treat both inflammatory disorders and cancers. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulatory role. In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.
Study: NCT02154919

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Study: NCT04054141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mag Stim
Description: rTMS
Study: NCT00694018

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and standard care
Description: Educational program for individuals with chronic back pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and standard care
Description: Educational program for individuals with chronic back pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet mediated enhanced pedometer intervention
Description: Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
Study: NCT02674347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 g or 6 g Zidebactam
Description: IV for over a duration of 60 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV matching the Investigational drug
Study: NCT00622505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Zoledronic acid concentrate (4 mg/5 milliliters \[ml\]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.
Study: NCT04577430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose with 1 μg/kg, maintenance dose with 1 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline is used to observe the effect on the electrophysiology of the patients' hearts
Study: NCT04486014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Erector Spinae Group (Group E) will receive bilateral ultrasound-guided erector spinae plane block using 30 ml hyperbaric bupivacaine 0.25% will be injected between erector spinae muscle and transverse process of T4

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block
Description: Serratus anterior Group (Group S) will undergo bilateral ultrasound-guided serratus anterior plane block with 30 ml hyperbaric bupivacaine 0.25% will be injected above or below serratus anterior muscle at the level of 4th and 5th rib on the midaxillary line
Study: NCT04054076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefabricated insoles
Description: The participants received prefabricated insoles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft custom-made insoles
Description: The participants received soft custom-made insoles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hard custom-made insoles
Description: The participants received hard custom-made insoles
Study: NCT02094092

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ProTectis drops (five drops per day) for 21 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drops (five drops per day) for 21 days
Study: NCT00933868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Chloride
Description: An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
Study: NCT03346122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 2
Description: Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 3
Description: Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 4
Description: Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 5
Description: Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 6
Description: Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
Study: NCT04336072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RFPP

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TFCBT
Study: NCT03863431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-fat diet
Description: Participants will consume a high fat diet for 14 days with approximately 65% of energy from fat. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-carbohydrate diet
Description: Participants will consume a high fat diet for 14 days with approximately 70% of energy from carbohydrate. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study.
Study: NCT04498442

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simha Kriya
Description: Simha-Kriya involves deep breathing exercises and meditation. It is the practice of extending the breath, expanding our lung capacity and mental concentration and energizing the body. Simha Kriya, when practiced intentionally will unite the mental, physical, and spiritual body through the breath. For the purpose of this study we advocate practice of Simha Kriya at least once a day.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reading a Book
Description: Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. Reading a book is often inculcated into mindfulness research due to it's impact on the personality and attitude. The simple act of reading a book can have a significant impact on their attitudes and can help them cope better with stress. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely for 15 minutes each day. Reading a book could potentially be substituted with sitting idle for 15 minutes if participants wishes to.